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Two kinds of truncated human c-myc proteins were produced in Escherichia coli. The human c-myc gene is composed 
of three exons, exons 2 and 3 having coding capacity for a protein of 439 amino acids. 252 N-terminal amino acids are 
encoded by exon 2, the C-terminal 187 amino acids being encoded by exon 3. One of the proteins (p42) produced in 
E. coli corresponds to 342 amino acids from the 98th Gin to the C-terminus, plus 21 amino acids derived from the H-ras 
gene at the N-terminus. The other (p23) corresponds to 155 amino acids from the 98th Gln to the 252nd Ser, plus five 
amino acids (Gly-Gly-Thr-Arg-Arg) at the C-terminus, plus 21 amino acids from the H-ras gene at the N-terminus. The 
p23 protein was produced by using cDNA in which a frame shift occurred at the boundary between exons 2 and 3. We 
investigated the DNA-binding activity in p42 and p23 proteins. DNA-cellulose column chromatography showed that 
p42 binds to DNA, whereas p23 does not. This DNA-binding activity of p42 was inhibited by antiserum prepared against 
p42 but not by antiserum against ~23. This indicates that the DNA-binding activity of c-myc protein is localized in the 
portion encoded by exon 3. 
recombinant DNA; c-myc protein; DNA-binding activity 
1. INTRODUCTION 
The c-myc gene, first identified as a cellular 
counterpart of the transforming gene of avian 
myelocytomatosis virus MC29 [l], is found in all 
vertebrate animals [2]. The c-myc protein is 
localized in the nucleus [3], and is associated with 
the nuclear matrix [4]. The c-myc protein produced 
in E. coli exhibits a high sequence-nonspecific af- 
finity for double-stranded DNA [5]. The human c- 
myc gene is composed of three exons, exons 2 and 
Correspondence address: Y. Kurosawa, Institute for Com- 
prehensive Medical Science, Fujita-Gakuen Health University, 
Toyoake, Aichi 470-l 1, Japan 
Abbreviations: ABC, avidin-biotin complex; DTT, 
dithiothreitol; FCS, fetal calf serum; NP40, Nonidet P-40; 
PAGE, polyacrylamide gel electrophoresis; PBS, phosphate- 
buffered saline; PMSF, phenylmethylsulphonyl fluoride 
3 having coding capacity for a protein of 439 
amino acids [6]. The N-terminal 252 amino acids 
are encoded by exon 2, the C-terminal 187 amino 
acids being encoded by exon 3. Recent analyses us- 
ing deletion and insertion mutants of c-myc-coding 
domains by Sarid et al. [7] and Stone et al. [8] 
defined the functional regions in c-myc protein for 
subcellular localization and transforming ability. 
Here, we produced two kinds of truncated human 
c-myc proteins in E. coli, prepared two kinds of 
antisera against both proteins, and show that the 
DNA-binding activity of c-myc protein is localized 
in the exon 3-encoded region. 
2. MATERIALS AND METHODS 
2.1. Bacteria, plasmids and cells 
E. coli 803 (rk-,mk-,Sulll+), obtained from K. Murray 
(University of Edinburgh), was used as the host for preparation 
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Fig.1. Construction of pTRmycl0. Physical map of the full- 
length cDNA of c-myc gene is shown at the top. We constructed 
a cDNA library from Daudi mRNA by the ordinary dG-dC 
tailing method [20] in pBR322, and four independent cDNA 
clones (pDNmycl-4) were obtained by colony hybridization 
[20] with v-myc probe [9]. The longest clone, pDNmyc1, covers 
the range from the 5’-side of the PvuII site in exon 2 to the 
3’-end of the gene. The PvuII-BumHI fragment of pCNRA1 
which directs the expression of the fused H-ru.s and human N- 
ras genes in E. coli [lo] was replaced by the PvuII-EC/~ fragment 
of pDNmyc1, resulting in plasmid pTRmycl0. The PvuII-C/u1 
fragment of pTRmycl0 was replaced by the PvuII-CluI 
fragment of pDNmyc3, resulting in pTRmyc22. Its primary 
structure is the same as that of pTRmycl0 except for the 
boundary between exons 2 and 3 (see section 3). 
of plasmid DNAs, and grown in L-broth. E. coli W3110 was 
used as the host for production of truncated c-myc proteins. A 
Burkitt lymphoma cell line, Daudi, was obtained from L.J. Old 
(Memorial Sloan-Kettering Cancer Center, New York). Plasmid 
pMC3 [9] containing the v-myc gene was supplied by Y. Taya 
(National Cancer Center, Tokyo). The expression vectors, 
pKYP200 and pCNRA1, have been described previously [lo]. 
Fig.2. (A) Expression of truncated fused c-myc gene in E. coli. 
(lane 1) pTRmyclO-, (lane 2) pTRmyc22-, (lane 3) 
pKYPZO@-transfected W3110 cells were grown to stationary 
phase in M9 medium supplemented with 0.5% casamino acids 
and 25 yg ampicillin/ml, harvested by centrifugation, and 
suspended in Laemmli buffer (125 mM Tris-HCI, pH 6.8, 4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.002% 
bromophenol blue). Total proteins were analyzed by SDS- 
PAGE [2 11. The proteins were stained with Coomassie brilliant 
blue. (B) Western blots of p23 and ~42. Lanes: 1, pTRmyclO-, 
2, pTRmyc22-, 3, pKYPZOO-transfected W3110. ‘251-labeled 
antibody was used. 
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Fig.3. DNA sequence of two kinds of cDNA clones and RNA 
splicing pathways. (a) DNA sequence ladder of the boundary 
between exons 2 and 3. DNA sequencing was performed 
according to Maxam and Gilbert [22]. (Left) pDNmyc3, (right) 
pDNmyc1. (b) Scheme of alternative RNA splicing pathways. 
2.2. Purification of truncated c-myc proteins 
pTRmyclO-transfected W3110 was grown in 6 I of M9 
medium supplemented with casamino acids. The inclusion 
bodies containing p23 were isolated as in [lo]. The final pellets 
were dissolved in 20 ml of 50 mM Tris-HCI (pH 8.0), 2 mM 
EDTA, 0.1 mM DTT, 5% glycerol, 0.1 mM PMSF and 8 M 
urea. This fraction contained 250 mg proteins of which p23 was 
approx. 60%. The sample was further purified by SDS-PAGE. 
The gel was sliced and the portion corresponding to p23 was re- 
tained. The proteins were electrically eluted from the gel (ISCO 
model 1750 sample collector) and dialyzed against 10 mM Tris- 
HCI (pH 8.0). SDS was removed from the protein sample using 
the ion-pair extraction method [ll]. p42 was similarly purified 
from pTRmyc22-infected W3110 according to the same 
protocol. 
2.3. Preparation of mouse antisera against p23 and p42 
(BALB/c x C57BL/6)F1 female mice were hyperimmunized 
with purified p23 or p42 at 2-week intervals. For the initial im- 
munization, 5Opg c-myc proteins were inoculated sub- 
cutaneously with complete Freund’s adjuvant. Subsequent 
immunizations were carried out by intraperitoneal inoculations 
of 100 pg c-myc proteins. The titer of antibodies against p23 or 
p42 was monitored by’ enzyme-linked immunosorbent assay. 
Mouse sera immunized more than 4 times were collected and 
pooled. The characterization of the anti-p23 and anti-p42 sera 
will be published elsewhere. The sera were used for Western 
blots at lOO-times dilution, and for assaying inhibition of DNA 
binding without dilution. 
2.4. Western blots 
Proteins separated by SDS-PAGE were electroblotted onto a 
nitrocellulose membrane (Scheicher & Schull BA85) as de- 
scribed by Towbin et al. [12]. The membrane was preincubated 
in 2% non-fat dry milk-containing PBS for 1 h, then incubated 
with anti-p23 antiserum diluted to l/100 in buffer A (PBS con- 
taining 2% FCS and 0.5% Tween 20) for 1 h at room 
temperature. The membrane was washed several times with buf- 
fer A, incubated with ‘251-labeled sheep anti-mouse im- 
munoglobulin antibodies (Amersham, 0.4&i/ml) in 5 ml 
buffer A for 1 h at room temperature, washed several times 
with buffer A, dried and exposed to X-ray film. Avidin-biotin 
complex (ABC) techniques were also employed (Vector Labs, 
USA). 
3. RESULTS AND DISCUSSION 
3.1. Construction of recombinant plasmids that 
direct the expression of truncated human 
c-myc proteins in E. coli 
We isolated c-myc cDNA clones in an attempt to 
produce human c-myc protein in E. co/i, and suc- 
ceeded in producing a truncated molecule encoded 
by pTRmyc10 (fig.1). It includes double trp pro- 
moters, the N-terminal 21 amino acids derived 
from the H-ras gene, the truncated c-myc gene 
from the PvuII site in exon 2 to the C-terminus and 
a terminator. When total proteins from 
pTRmyclO- and pKYP200-transfected E. c&i 
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bacteria were analyzed by SDS-PAGE, an extra 
band of high intensity was observed at 23 kDa in 
the former preparation (fig.2A). The 23 kDa 
polypeptide (~23) was purified and its primary 
structure was analyzed. The C-terminal amino acid 
was arginine, which does not correspond to that of 
normal c-myc protein, alanine. Since the molecular 
mass of p23 protein was much less than the ex- 
pected 42 kDa, we determined the nucleotide se- 
quence of the cDNA clones. We found an 
unexpected feature at the boundary between exons 
2 and 3. Fig.3a shows two typical examples of the 
sequence ladder. The sequence in pDNmyc3 is 
GACTCTG/AGGAGGAA (type I), the same as 
reported in [13]. However, the sequence in 
pDNmyc1, which was used to construct 
pTRmycl0, is GACTCTGIGAGGAA (type II), 
resulting in a frame shift of c-myc protein. The 
primary structure of the p23 protein deduced from 
the nucleotide sequence of the constructed plasmid 
was as follows: the N-terminal 21 amino acids 
derived from the H-ras gene, and 155 amino acids 
encoded by a part of the c-myc gene from the 
PvuII site to the 3’-end of exon 2, plus 5 amino 
acids (Gly-Gly-Thr-Arg-Arg). 
To obtain a c-myc protein including the exon 
3-encoded portion, we constructed plasmid 
pTRmyc22 as described in the legend to fig.1. 
Analysis of total proteins from pTRmyc22- 
infected bacteria showed a thick band at 42 kDa 
(fig.2A). Since pKYP200-infected bacteria also 
showed a thick band at he same size, immunoblot- 
tings were carried out with the murine antiserum 
prepared against p23 to determine whether p42 
observed in pTRmyc22-infected bacteria contains 
a c-myc protein. Fig.2B clearly shows that the p42 
fraction in pTRmyc22-transfected bacteria con- 
tains a large amount of c-myc proteins. The weak 
bands observed at lower molecular masses (panel 
B, lane 2) might be degradation products. 
3.2. DNA-binding activity of c-myc protein is 
localized in the exon 3-encoded region 
To ascertain whether p42 and p23 bind to DNA, 
they were purified from pTRmyc22- and 
pTRmyclO-transfected bacteria, respectively, and 
analyzed on a DNA-cellulose column (fig.4) [14]. 
The protein band was observed at 42 kDa in the 
0.5 M NaCl eluate in the case of p42 being applied. 
No p23 was retained on the DNA-cellulose column 
Fig.4. DNA-cellulose cohmm chromatography of ~42. p42 proteins were purified as described in section 2. (a) 2 pg p42 were dissolved 
in 10 pl buffer B (50 mM Tris-HCI, pH 6.8, 0.5% NP40), and applied to double-stranded calf thymus DNA-cellulose (Pharmacia) 
columns (bed volume 0.2 ml) which had been equilibrated with buffer B. Columns were then washed with 5 bed volumes of buffer 
B. Proteins bound to the columns were eluted by increasing salt concentrations in buffer B. Proteins in each fraction were precipitated 
in 5% trichloroacetic acid, resolved in Laemmli buffer, and analyzed by SDS-PAGE [lanes: (1) flow through: (2) 0 mM NaCl wash; 
(3) 1 bed volume, 100 mM NaCI; (4) 5 bed volumes, 100 mM NaCI; (5) 1 bed volume, 500 mM NaCI]. Proteins were identified on 
Western blots using the ABC system. (b) The flow-through fraction was re-applied to the DNA-cellulose column and eluted as above 
(1,O mM NaCI; 2, 100 mM NaCI; 3. 500 mM NaCl). (c) The 500 mM NaCl eluate (lane 5) was re-applied to the DNA-cellulose column 
after dialysis against buffer B, and eluted (1, 0 mM NaCI; 2, 100 mM NaCI; 3, 500 mM NaCI). 
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(not shown). Since more than half of p42 was 
observed in the flow-through fraction, both the 
flow-through and retained fractions of p42 were 
recovered and applied again to the DNA-cellulose 
column. One-third of the retained fraction was 
bound to DNA once more. The reason why a por- 
tion of p42 was observed in the flow-through frac- 
tion may be that the renaturation of p42 was 
incomplete in our preparation and/or p42 was 
unstable. This suggests that p42 has DNA-binding 
activity. To determine whether the DNA-binding 
activity of p42 is localized in the exon 3-encoded 
region, which p23 does not contain, we prepared 
two kinds of antisera against p42 and ~23. As 
shown in fig.5, anti-p23 did not exert any influence 
on the DNA-binding site in p42 (lane 2) although 
binding of p42 to the DNA column was completely 
blocked by anti-p42 serum (lane 1). This indicates 
Fig.5. Effects of antisera on DNA-binding activity of ~42. 2 /g 
p42 and 2 pl antiserum were incubated overnight at 4°C 
p42-antibody complex was applied to the DNA-cellulose 
column, then washed with 5 bed volumes of buffer B and 
successively 5 bed volumes of buffer B containing 100 mM 
NaCI. p42 bound to the DNA-cellulose column was eluted by 
500 mM NaCl in buffer B. Proteins eluted by 500 mM NaCl 
were precipitated in 5% trichloroacetic acid and analysed on 
SDS-PAGE and Western blots using the ABC system (1, anti- 
p42 antiserum against ~42; 2, antiserum against ~23; 3, non- 
immunized mouse antiserum). 
that DNA-binding activity is localized in the por- 
tion encoded by exon 3. 
The DNA-binding region of c-myc protein has 
been believed to be localized in the 3 ‘-domain of 
the molecule, based on the following observations. 
First, the specific antibody against this domain 
strongly inhibits binding of the molecule to DNA 
[15]. Second, homology between the amino acid 
sequence of c-myc protein and those of other 
DNA-binding proteins such as myb, Ela, fos and 
jun has been found mainly in the C-terminal region 
of c-myc [16,17]. There are several examples of 
DNA binding mediated through a helix-turn-helix 
structure [18], and computer analyses using the 
program of Chou and Fasman [19] predict that the 
secondary structure of the C-terminal region of c- 
myc would prefer an a-helical conformation. 
Here, we prepared two kinds of truncated c-myc 
molecules in E. coli, of which p42 contains an exon 
3-encoded region whereas p23 does not, and direct- 
ly showed that the exon 3-encoded portion has 
DNA-binding activity. 
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